ClinicalTrials.gg
CompletedNCT00790205TECOSUpdated Nov 23, 2021Results posted

Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)

A Phase 3 interventional study of Sitagliptin and Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-11-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14,671
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
Largest of 197
14,671 · median 102
Started
2008
with 22 others
Phase 3
74 of 198
none open now
Registered
57th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one has the largest enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 57th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment with sitagliptin used as part of usual care compared to usual care without sitagliptin in participants with type 2 diabetes mellitus (T2DM) having a history of cardiovascular (CV) disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%.

Primary hypothesis A is that sitagliptin, when used as part of usual care, is non-inferior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint of Major Adverse Cardiovascular Event (MACE) plus. If hypothesis A is satisfied: hypothesis B is that sitagliptin, when used as part of usual care, is superior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has T2DM
  • Has between 6.5% (48 mmol/mol) and 8.0% (64 mmol/mol) on stable dose(s) of antihyperglycemic agent(s), including insulin
  • Has pre-existing cardiovascular disease

Exclusion criteria

Exclusion Criteria:

  • Has a history of type 1 diabetes mellitus or ketoacidosis.
  • Is not able to take sitagliptin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
14,671 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.

    Drug: Sitagliptin

  • Placebo comparator
    Placebo

    Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.

    Drug: Placebo

Interventions

  • Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.

    Also known as: MK-0431, Januvia®

  • DrugPlacebo

    Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population)

    Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.

    Time frame: Up to 5 years

  2. Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population)

    Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.

    Time frame: Up to 5 years

Secondary outcomes

  1. Percentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population)

    CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.

    Time frame: Up to 5 years

  2. Percentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population)

    CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.

    Time frame: Up to 5 years

  3. Percent Incidence of All-cause Mortality (Per Protocol Population)

    Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.

    Time frame: Up to 5 years

  4. Percent Incidence of All-cause Mortality (Intent to Treat Population)

    Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.

    Time frame: Up to 5 years

  5. Percent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population)

    Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.

    Time frame: Up to 5 years

  6. Percent Incidence of CHF Requiring Hospitalization (Intent to Treat Population)

    Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.

    Time frame: Up to 5 years

  7. Change From Baseline in Renal Function Over Time (Per Protocol Population)

    Change in renal function based on estimated glomerular filtration rate \[eGFR\] using the Modification of Diet in Renal Disease \[MDRD\] method.

    Time frame: Baseline and up to 5 years

  8. Change From Baseline in Renal Function Over Time (Intent to Treat Population)

    Change in renal function based on eGFR using the MDRD method.

    Time frame: Baseline and up to 5 years

  9. Change From Baseline in HbA1c Over Time (Per Protocol Population)

    HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.

    Time frame: Baseline and up to 4 years

  10. Change From Baseline in HbA1c Over Time (Intent to Treat Population)

    HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.

    Time frame: Baseline and up to 4 years

  11. Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Per Protocol Population)

    Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.

    Time frame: Baseline and up to 5 years

  12. Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Intent to Treat Population)

    Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.

    Time frame: Baseline and up to 5 years

  13. Percentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population)

    Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.

    Time frame: Up to 5 years

  14. Percentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population)

    Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.

    Time frame: Up to 5 years

  15. Percentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population)

    In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent \[AHA\] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)

    Time frame: Up to 5 years

  16. Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population)

    In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)

    Time frame: Up to 5 years

07

Results

Posted Apr 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinPlacebo
Started73327339
Treated72667274
Completed69726905
Not completed360434
Withdrew: Lost to follow-up6171
Withdrew: Withdrawal by subject299363

Outcome measures

PrimaryPercentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population)

Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population)9.69.6
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = <0.001 · Hazard ratio (hr): 0.98 · 95% CI 0.88 to 1.09Model stratified by region with treatment group only as explanatory variable.
PrimaryPercentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population)

Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population)11.411.6
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = <0.001 · Hazard ratio (hr): 0.98 · 95% CI 0.89 to 1.08Model stratified by region with treatment group only as explanatory variable.
SecondaryPercentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population)

CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population)8.48.3
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = <0.001 · Hazard ratio (hr): 0.99 · 95% CI 0.89 to 1.11Model stratified by region with treatment group only as explanatory variable.
SecondaryPercentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population)

CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population)10.210.2
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = <0.001 · Hazard ratio (hr): 0.99 · 95% CI 0.89 to 1.10Model stratified by region with treatment group only as explanatory variable.
SecondaryPercent Incidence of All-cause Mortality (Per Protocol Population)

Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percent Incidence of All-cause Mortality (Per Protocol Population)
Percentage of participantsSitagliptinPlacebo
Percent Incidence of All-cause Mortality (Per Protocol Population)4.74.3
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = 0.435 · Hazard ratio (hr): 1.06 · 95% CI 0.91 to 1.24
SecondaryPercent Incidence of All-cause Mortality (Intent to Treat Population)

Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percent Incidence of All-cause Mortality (Intent to Treat Population)
Percentage of participantsSitagliptinPlacebo
Percent Incidence of All-cause Mortality (Intent to Treat Population)7.57.3
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = 0.875 · Hazard ratio (hr): 1.01 · 95% CI 0.90 to 1.14
SecondaryPercent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population)

Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population)
Percentage of participantsSitagliptinPlacebo
Percent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population)2.8 (1.00 to 1.53)2.8 (0.84 to 1.33)
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = 0.858 · Hazard ratio (hr): 0.98 · 95% CI 0.81 to 1.19Model stratified by region with treatment group and history of CHF at baseline as explanatory variables.
SecondaryPercent Incidence of CHF Requiring Hospitalization (Intent to Treat Population)

Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percent Incidence of CHF Requiring Hospitalization (Intent to Treat Population)
Percentage of participantsSitagliptinPlacebo
Percent Incidence of CHF Requiring Hospitalization (Intent to Treat Population)3.1 (1.00 to 1.53)3.1 (0.84 to 1.33)
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = 0.983 · Hazard ratio (hr): 1.00 · 95% CI 0.83 to 1.20Model stratified by region with treatment group and history of CHF at baseline as explanatory variables.
SecondaryChange From Baseline in Renal Function Over Time (Per Protocol Population)

Change in renal function based on estimated glomerular filtration rate \[eGFR\] using the Modification of Diet in Renal Disease \[MDRD\] method.

Time frame:
Baseline and up to 5 years
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline in Renal Function Over Time (Per Protocol Population)
mL/min/1.73 m^2SitagliptinPlacebo
Month 4; Sitagliptin, n= 3859; Placebo, n= 3864-1.9 ± 14.2-0.8 ± 14.3
Month 8; Sitagliptin, n= 3562; Placebo, n= 3501-2.5 ± 14.9-0.9 ± 15.1
Month 12; Sitagliptin, n=4912, Placebo, n=4778-1.8 ± 15.8-0.5 ± 16.2
Month 24; Sitagliptin, n=4782, Placebo, n=4637-3.1 ± 17.9-1.7 ± 17.5
Month 36; Sitagliptin, n=2776, Placebo, n=2614-3.7 ± 18.0-1.6 ± 18.8
Month 48; Sitagliptin, n=1096, Placebo, n=1056-3.7 ± 18.3-2.8 ± 18.4
Month 60; Sitagliptin, n=79, Placebo, n=88-3.5 ± 18.2-6.4 ± 17.3
SecondaryChange From Baseline in Renal Function Over Time (Intent to Treat Population)

Change in renal function based on eGFR using the MDRD method.

Time frame:
Baseline and up to 5 years
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline in Renal Function Over Time (Intent to Treat Population)
mL/min/1.73 m^2SitagliptinPlacebo
Month 4; Sitagliptin, n=3949; Placebo, n=3977-1.8 ± 14.3-0.8 ± 14.3
Month 8; Sitagliptin, n=3687; Placebo, n=3648-2.4 ± 14.8-0.9 ± 15.2
Month 12; Sitagliptin, n=5082; Placebo, n=5015-1.8 ± 15.8-0.5 ± 16.3
Month 24; Sitagliptin, n=5157; Placebo, n=5071-3.2 ± 17.9-1.7 ± 17.7
Month 36; Sitagliptin, n=3037; Placebo, n=2942-3.8 ± 18.1-1.6 ± 18.7
Month 48; Sitagliptin, n=1237; Placebo, n=1210-4.0 ± 18.4-2.8 ± 18.3
Month 60; Sitagliptin, n=93; Placebo, n=106-4.2 ± 17.4-5.7 ± 17.2
SecondaryChange From Baseline in HbA1c Over Time (Per Protocol Population)

HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.

Time frame:
Baseline and up to 4 years
Reported as:
Mean · Percentage of HbA1c
Change From Baseline in HbA1c Over Time (Per Protocol Population)
Percentage of HbA1cSitagliptinPlacebo
Month 4; Sitagliptin, n=6632, Placebo, n=6588-0.3 ± 0.80.1 ± 0.9
Month 8; Sitagliptin, n=6294, Placebo, n=6197-0.3 ± 0.90.1 ± 1.0
Month 12; Sitagliptin, n=6217, Placebo, n=6092-0.2 ± 1.00.1 ± 1.0
Month 24; Sitagliptin, n=5668, Placebo, n=5475-0.1 ± 1.00.2 ± 1.1
Month 36; Sitagliptin, n=3227, Placebo, n=3083-0.1 ± 1.10.1 ± 1.1
Month 48; Sitagliptin, n=1271, Placebo, n=12240.0 ± 1.10.1 ± 1.2
Month 60; Sitagliptin, n=106, Placebo, n=108-0.1 ± 1.00.0 ± 0.9
SecondaryChange From Baseline in HbA1c Over Time (Intent to Treat Population)

HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.

Time frame:
Baseline and up to 4 years
Reported as:
Mean · Percentage of HbA1c
Change From Baseline in HbA1c Over Time (Intent to Treat Population)
Percentage of HbA1cSitagliptinPlacebo
Month 4: Sitagliptin, n= 6772; Placebo, n= 6738-0.3 ± 0.80.1 ± 0.9
Month 8: Sitagliptin, n= 6478; Placebo, n= 6414-0.2 ± 0.90.1 ± 1.0
Month 12: Sitagliptin, n= 6448; Placebo, n= 6384-0.2 ± 1.00.1 ± 1.0
Month 24: Sitagliptin, n= 6105; Placebo, n= 5975-0.1 ± 1.00.1 ± 1.1
Month 36: Sitagliptin, n= 3521; Placebo, n= 3439-0.1 ± 1.10.1 ± 1.1
Month 48: Sitagliptin, n= 1432; Placebo, n= 13830.0 ± 1.10.1 ± 1.2
Month 60: Sitagliptin, n= 123; Placebo, n= 1280.0 ± 1.00.0 ± 1.0
SecondaryChange From Baseline in Urine Albumin:Creatinine Ratio Over Time (Per Protocol Population)

Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.

Time frame:
Baseline and up to 5 years
Reported as:
Mean · g/mol Creatinine
Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Per Protocol Population)
g/mol CreatinineSitagliptinPlacebo
Month 4; Sitagliptin, n=664; Placebo, n=688-2.2 ± 27.7-1.4 ± 24.6
Month 8; Sitagliptin, n=635; Placebo, n=5971.7 ± 38.50.2 ± 45.3
Month 12; Sitagliptin, n=1126; Placebo, n=10590.8 ± 27.71.2 ± 33.1
Month 24; Sitagliptin, n=930; Placebo, n=8920.7 ± 34.03.2 ± 31.6
Month 36; Sitagliptin, n=488; Placebo, n=5132.5 ± 24.04.0 ± 31.0
Month 48; Sitagliptin, n=238; Placebo, n=2331.3 ± 15.21.5 ± 25.5
Month 60; Sitagliptin, n=13; Placebo, n=17-2.7 ± 10.14.8 ± 15.4
SecondaryChange From Baseline in Urine Albumin:Creatinine Ratio Over Time (Intent to Treat Population)

Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.

Time frame:
Baseline and up to 5 years
Reported as:
Mean · g/mol Creatinine
Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Intent to Treat Population)
g/mol CreatinineSitagliptinPlacebo
Month 4; n=677, n=713-2.1 ± 27.5-1.4 ± 24.1
Month 8; n=658, n=6242.1 ± 39.40.5 ± 44.5
Month 12; n=1167, n=11151.3 ± 30.21.2 ± 32.3
Month 24; n=1011, n=9640.5 ± 33.13.1 ± 30.7
Month 36; n=537, n=5532.6 ± 25.83.9 ± 30.3
Month 48; n=265, n=2561.9 ± 16.31.6 ± 24.5
Month 60; n=14, n=18-2.5 ± 9.76.4 ± 16.4
SecondaryPercentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population)

Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population)8.611.9
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = <0.001 · Hazard ratio (hr): 0.69 · 95% CI 0.61 to 0.77Model stratified by region with treatment group only as explanatory variable.
SecondaryPercentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population)

Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population)9.713.2
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = <0.001 · Hazard ratio (hr): 0.70 · 95% CI 0.63 to 0.79Model stratified by region with treatment group only as explanatory variable.
SecondaryPercentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population)

In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent \[AHA\] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population)18.924.5
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = <0.001 · Hazard ratio (hr): 0.70 · 95% CI 0.65 to 0.75Model stratified by region with treatment group only as explanatory variable.
SecondaryPercentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population)

In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population)21.727.9
Statistical analysis
  • Sitagliptin vs Placebo · Cox proportional hazards model · p = <0.001 · Hazard ratio (hr): 0.72 · 95% CI 0.68 to 0.77Model stratified by region with treatment group only as explanatory variable.

Adverse events

Collected over Up to 68 months (including up to 28 days after last dose of study drug). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—928/7,266 (12.8%)0/7,266 (0%)
Placebo—909/7,274 (12.5%)0/7,274 (0%)
Most frequent serious events
Showing 10 of 732
Most frequent serious events
EventSitagliptinPlacebo
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)44/726655/7274
OsteoarthritisMusculoskeletal and connective tissue disorders52/726635/7274
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)36/726645/7274
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)26/726638/7274
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders13/726630/7274
Non-cardiac chest painGeneral disorders17/726626/7274
AnaemiaBlood and lymphatic system disorders23/726623/7274
HyponatraemiaMetabolism and nutrition disorders8/726621/7274
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)12/726620/7274
Accidental overdoseInjury, poisoning and procedural complications17/726619/7274

Baseline characteristics

Age, Customized
Age, Customized(Participants)SitagliptinPlaceboTotal
Adults 18 - 64 years3315 ± 7.93301 ± 8.065.5 ± 8.0
From 65 - 84 years381338217634
85 years and over4655101
Unknown age158162320
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlaceboTotal
Female213421634297
Male5198517610374
Estimated Glomerular Filtration Rate (eGFR)
Estimated Glomerular Filtration Rate (eGFR)(mL/min/1.73 m^2)SitagliptinPlaceboTotal
Mean74.9 ± 21.374.9 ± 20.974.9 ± 21.1
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percentage of HbA1c)SitagliptinPlaceboTotal
Mean7.2 ± 0.57.2 ± 0.57.2 ± 0.5
Urine albumin creatinine ratio
Urine albumin creatinine ratio(g/mol Creatinine)SitagliptinPlaceboTotal
Mean8.6 ± 37.48.4 ± 36.08.5 ± 36.7
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013 Dec;166(6):983-989.e7. doi: 10.1016/j.ahj.2013.09.003. Epub 2013 Oct 23. PubMed 24268212 ↗
  • Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR; TECOS Executive Committee. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab. 2015 Apr;17(4):395-402. doi: 10.1111/dom.12441. Epub 2015 Feb 13. PubMed 25600421 ↗
  • Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum In: N Engl J Med. 2015 Aug 6;373(6):586. doi: 10.1056/NEJMx150029. PubMed 26052984 ↗
  • Sharma A, Zheng Y, Ezekowitz JA, Westerhout CM, Udell JA, Goodman SG, Armstrong PW, Buse JB, Green JB, Josse RG, Kaufman KD, McGuire DK, Ambrosio G, Chuang LM, Lopes RD, Peterson ED, Holman RR. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes Care. 2022 Jan 1;45(1):204-212. doi: 10.2337/dc20-2806. PubMed 34716214 ↗
  • McAlister FA, Zheng Y, Westerhout CM, Buse JB, Standl E, McGuire DK, Van de Werf F, Green JB, Armstrong PW, Holman RR; TECOS Study Group. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. Eur J Heart Fail. 2020 Nov;22(11):2026-2034. doi: 10.1002/ejhf.1958. Epub 2020 Jul 28. PubMed 32621557 ↗
  • De Ferrari GM, Stevens SR, Ambrosio G, Leonardi S, Armstrong PW, Green JB, Wamil M, Holman RR, Peterson ED; TECOS Study Group. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. Am Heart J. 2020 Feb;220:82-88. doi: 10.1016/j.ahj.2019.11.005. Epub 2019 Nov 13. PubMed 31790905 ↗
  • Shavadia JS, Zheng Y, Green JB, Armstrong PW, Westerhout CM, McGuire DK, Cornel JH, Holman RR, Peterson ED. Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. Am Heart J. 2019 Dec;218:92-99. doi: 10.1016/j.ahj.2019.09.013. Epub 2019 Oct 20. PubMed 31715435 ↗
  • Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. Cardiovasc Diabetol. 2019 Sep 3;18(1):116. doi: 10.1186/s12933-019-0921-2. PubMed 31481069 ↗
  • Guimaraes PO, Peterson ED, Stevens SR, Lokhnygina Y, Green JB, McGuire DK, Holman RR, Lopes RD. Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. Int J Cardiol. 2019 Aug 15;289:58-62. doi: 10.1016/j.ijcard.2019.04.085. Epub 2019 Apr 30. PubMed 31079973 ↗
  • Reed SD, Li Y, Leal J, Radican L, Adler AI, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR; TECOS Study Group. Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab. 2018 Jul;20(7):1732-1739. doi: 10.1111/dom.13292. Epub 2018 Apr 20. PubMed 29573215 ↗
  • Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care. 2018 Mar;41(3):596-603. doi: 10.2337/dc17-1778. Epub 2018 Jan 8. PubMed 29311155 ↗
  • Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care. 2017 Dec;40(12):1763-1770. doi: 10.2337/dc17-1091. Epub 2017 Oct 6. PubMed 28986504 ↗
  • Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED; TECOS Study Group. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). Circulation. 2017 Sep 26;136(13):1193-1203. doi: 10.1161/CIRCULATIONAHA.117.027252. Epub 2017 Jun 16. PubMed 28626088 ↗
  • Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, Peterson ED, Holman RR; TECOS Study Group. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care. 2017 Apr;40(4):494-501. doi: 10.2337/dc16-1135. Epub 2017 Jan 5. PubMed 28057693 ↗
  • Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec;39(12):2304-2310. doi: 10.2337/dc16-1415. Epub 2016 Oct 14. PubMed 27742728 ↗
  • Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group. Pancreatic Safety of Sitagliptin in the TECOS Study. Diabetes Care. 2017 Feb;40(2):164-170. doi: 10.2337/dc15-2780. Epub 2016 Sep 14. PubMed 27630212 ↗
  • McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 May 1;1(2):126-35. doi: 10.1001/jamacardio.2016.0103. PubMed 27437883 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Mar 2015, 75 months.

Results were first posted in Apr 2016, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 75 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2008
First posted
Nov 13, 2008
StartActual
Dec 10, 2008
Primary completionActual
Mar 30, 2015
CompletionActual
Mar 30, 2015
Results first posted
Apr 15, 2016
Last update
Nov 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00790205
Collaborators
Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Responsible party
Sponsor
First posted
Nov 13, 2008
Start date
Dec 10, 2008
Primary completion
Mar 30, 2015
Completion
Mar 30, 2015
Results posted
Apr 15, 2016
Last update
Nov 23, 2021

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion